Pancreatin (Pancreatic Enzyme Replacement Therapy — PERT)
Brand names: Creon, Nutrizym, Pancrease HL
Pancreatin provides pancreatic enzyme replacement therapy and is used to treat exocrine pancreatic insufficiency, for example in cystic fibrosis, chronic pancreatitis and after pancreatic surgery.
ClinCalc Pro is rebuilding its dose data from primary open sources — the manufacturer SmPC (eMC), the WHO Model Formulary and other official references — under clinician review. This drug's structured dose is not yet published here. Confirm all doses against the product SmPC and your local formulary before prescribing.
Clinical monograph
How it works
It supplies the digestive enzymes lipase, amylase and protease, replacing deficient pancreatic secretions to aid the breakdown and absorption of fat, carbohydrate and protein.
Prescribing in practice
- Very high doses of high-strength preparations have been linked to fibrosing colonopathy, particularly in children with cystic fibrosis, so the total enzyme intake should be kept within recommended limits.
- Capsules and their granules should be taken with meals and snacks and not chewed, so the enzymes are released in the small bowel.
- Ensure adequate hydration, as inadequate fluid intake may contribute to bowel complications.
Monitoring
Monitor nutritional status, growth in children and control of steatorrhoea, adjusting the dose to symptoms and dietary fat intake.
Counselling the patient
- Advise patients to take the enzymes with every meal and snack and to swallow capsules whole, or sprinkle the granules onto soft acidic food without chewing.
- Explain that the dose may need adjusting with the fat content of meals and to report persistent diarrhoea or abdominal pain.
Evidence & guidelines
Pancreatic enzyme replacement therapy is the standard of care for exocrine pancreatic insufficiency, supported by NICE guidance on cystic fibrosis and pancreatitis.
Reference: Cystic Fibrosis Trust — PERT Guidelines; SPC Creon; Drug verified in RxNorm (NLM); confirm dosing against the manufacturer SPC (eMC). Verify against your local formulary and current prescribing references before prescribing. Monograph status: clinician-reviewed (2026-07-04).
Related
Curated clinical cross-links plus same-class fallbacks.
- DAPT Score for Dual Antiplatelet Therapy Duration · Antiplatelet Therapy
- ACC/AHA Pooled Cohort Equations (ASCVD Risk) · Cardiovascular Risk
- DAPT Decision Tool (Ticagrelor vs Clopidogrel) · Antiplatelet Therapy
- Weight-Based Levothyroxine Dose Calculator · Thyroid
- Travis Criteria for Severe Ulcerative Colitis · Inflammatory Bowel Disease
- Pancreatic Fistula Risk Score (FRS) after Pancreatoduodenectomy · Pancreatic Surgery
- Lower Gastrointestinal Bleed · BSG 2019; NICE NG141
- Variceal Upper GI Bleed · BSG 2015; Baveno VII (2022)
- Spontaneous Bacterial Peritonitis (SBP) · BSG / EASL 2018
- Hepatorenal Syndrome · EASL 2018; ICA 2015
- Hepatic Encephalopathy · EASL 2014; West Haven criteria
- Clostridioides difficile Colitis · NICE NG199 (2021); IDSA/SHEA 2021